Jonathan M. Loree

Jonathan M. Loree

Vancouver, BC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 154 publications

Dual versus single-agent immune checkpoint inhibitor therapy in microsatellite instability-high metastatic colorectal cancer: an analysis based on reconstructed patient data.

Dual versus single-agent immune checkpoint inhibitor therapy in microsatellite instability-high metastatic colorectal cancer: an analysis based on reconstructed patient data.

Journal: ESMO gastrointestinal oncology

Published: August 12, 2026

Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White Paper.

Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White Paper.

Journal: Current oncology (Toronto, Ont.)

Published: April 29, 2026

Treatment attrition between lines of therapy and its impact on outcomes for well-differentiated neuroendocrine tumors in British Columbia.

Treatment attrition between lines of therapy and its impact on outcomes for well-differentiated neuroendocrine tumors in British Columbia.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Comparison of [111In]octreotide Scintigraphy and [68Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility.

Comparison of [111In]octreotide Scintigraphy and [68Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility.

Journal: Neuroendocrinology

Published: March 24, 2026

Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 26, 2026

Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms.

Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms.

Journal: Cell reports

Published: February 19, 2026

Comparison of Lanreotide and Octreotide LAR Use and Outcomes for Gastrointestinal Neuroendocrine Tumors in British Columbia, Canada.

Comparison of Lanreotide and Octreotide LAR Use and Outcomes for Gastrointestinal Neuroendocrine Tumors in British Columbia, Canada.

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: February 19, 2026

Systemic adjuvant and perioperative chemotherapy following curative-intent liver metastasectomy in colorectal cancer-is it justified?

Systemic adjuvant and perioperative chemotherapy following curative-intent liver metastasectomy in colorectal cancer-is it justified?

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

A framework to evaluate surrogate endpoints at the trial level: Analysis in colorectal cancer.

A framework to evaluate surrogate endpoints at the trial level: Analysis in colorectal cancer.

Journal: Journal of the National Cancer Institute

Published: November 26, 2025

Real-World Observational Study of Somatostatin Analogs and Rescue Medication Usage for Neuroendocrine Tumors in Canada.

Real-World Observational Study of Somatostatin Analogs and Rescue Medication Usage for Neuroendocrine Tumors in Canada.

Journal: Neuroendocrinology

Published: September 22, 2025

Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial.

Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial.

Journal: Nature medicine

Published: September 05, 2025

An asynchronous electronic consent for improving consent in research among patients with cancer.

An asynchronous electronic consent for improving consent in research among patients with cancer.

Journal: The oncologist

Published: July 24, 2025

Showing 1-12 of 154

Last Updated: 09/26/2026